I-Mab, a U.S.-based global biotech company focused on precision immuno-oncology agents, reported its financial results for the first quarter of 2025. The company recorded a net loss of $3.2 million for the three months ended March 31, 2025, a significant improvement from the net loss of $16.3 million in the same period in 2024. Interest income increased to $1.9 million from $0.7 million year-over-year, primarily due to higher interest rates earned on cash balances in 2025. Additionally, other income (expenses), net were $0.2 million compared to $(0.6) million in the previous year. Notably, there was no equity in loss of affiliates for the first quarter of 2025, compared to $1.0 million in losses during the same period in 2024. The company also highlighted its strong financial position with $168.6 million in cash and cash equivalents, and short-term investments as of March 31, 2025, providing a financial runway into 2027. The prioritization of givastomig as I-Mab's lead program positions the company for clinical progress, with new combination data for the drug selected for presentation at ESMO GI in July 2025.